Back HIV/AIDS HIV/AIDS Topics HIV Treatment

IAS 2015: START Supports ART For All [VIDEO]

Full results from the Strategic Timing of Antiretroviral Treatment (START) trial provide definitive evidence that starting antiretroviral therapy (ART) soon after HIV diagnosis, rather than waiting until the CD4 T-cell count falls below 500 cells/mm3, significantly reduces the risk of AIDS-related and non-AIDS illness and death, researchers reported at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention last month in Vancouver.

alt

Read more:

IAS 2015: WAVES Shows Elvitegravir Regimen Beats Boosted Atazanavir for Women with HIV

A study of antiretroviral treatment specifically for women with HIV showed that a single-tablet regimen containing the integrase inhibitor elvitegravir suppressed the virus better than a regimen containing ritonavir-boosted atazanavir, according to a poster presented at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention last month in Vancouver. This study is important in part because it demonstrates that including more women in clinical trials is feasible.

alt

Read more:

IAS 2015: Long-term HIV Remission [VIDEO]

A French teenager with HIV who has maintained an undetectable viral load for 12 years while off antiretroviral treatment was among the most widely discussed topics at the 8th International AIDS Society Conference last week in Vancouver. While no one is calling this case a cure, it does raise interesting questions about "post-treatment control" and may provide clues about how to achieve a functional cure or long-term HIV remission.

alt

Read more:

IAS 2015: Targets Proliferate in HIV Cure Research

The Towards an HIV Cure two-day symposium has become a fixture in advance of the International AIDS Society conferences and the meeting last week in Vancouver featured a more varied range of experimental approaches than ever in the search for ways of eliminating HIV infection from the body.

alt

Read more:

IAS 2015: Treatment Cascades Show 90-90-90 Goals Reachable, Eastern Europe Lags Behind Africa

A global analysis of HIV treatment cascades -- the proportions of people diagnosed with HIV, in care, on treatment, and virally suppressed -- shows that some of the world’s richest countries still fall far short of achieving the UNAIDS 90-90-90 targets, research from Imperial College London shows. Progress is worst in Eastern Europe, where most countries lag behind average performance in sub-Saharan Africa on every indicator.

alt

 

Read more:

White House Releases Updated National HIV/AIDS Strategy

On July 30 the White House released an updated version of its National HIV/AIDS Strategy, outlining the administration's plans through the year 2020. In keeping with recent research, the revised strategy includes an increased emphasis on early antiretroviral treatment and pre-exposure prophylaxis (PrEP), as well as focusing on underserved and heavily affected population groups including young gay men, transgender women, and African-Americans.

alt

Read more:

IAS 2015: Test and Treat Studies and African Country Experience Show 90-90-90 Targets Are Achievable

Health services in some African countries including Botswana, Rwanda, and Malawi are now providing effective HIV treatment to a greater proportion of their HIV-positive citizens than the U.S. and other rich countries. Meanwhile, some of the first data to come from large African studies examining the population-level impact of treatment as prevention suggest that the objectives of testing and treating 90% of those eligible can be achieved.

alt

Read more: